New York, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Intravenous (IV) Iron Drugs Industry" - https://www.reportlinker.com/p06051284/?utm_source=GNW
Online interactive peer-to-peer collaborative bespoke updates
Access to our digital archives and MarketGlass Research Platform
Complimentary updates for one year
Global Intravenous (IV) Iron Drugs Market to Reach $4.1 Billion by 2027
Amid the COVID-19 crisis, the global market for Intravenous (IV) Iron Drugs estimated at US$2.5 Billion in the year 2020, is projected to reach a revised size of US$4.1 Billion by 2027, growing at a CAGR of 7.1% over the analysis period 2020-2027. Ferric Carboxymaltose, one of the segments analyzed in the report, is projected to record a 7.7% CAGR and reach US$2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Iron Dextran segment is readjusted to a revised 6.4% CAGR for the next 7-year period.
The U.S. Market is Estimated at $689 Million, While China is Forecast to Grow at 11.5% CAGR
The Intravenous (IV) Iron Drugs market in the U.S. is estimated at US$689 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$912.5 Million by the year 2027 trailing a CAGR of 11.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.4% and 6.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.
Iron Sucrose Segment to Record 5.9% CAGR
In the global Iron Sucrose segment, USA, Canada, Japan, China and Europe will drive the 5.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$342.5 Million in the year 2020 will reach a projected size of US$494 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$562.4 Million by the year 2027, while Latin America will expand at a 7.2% CAGR through the analysis period.
Select Competitors (Total 21 Featured) -
Allergan Plc.
AMAG Pharmaceuticals Inc.
American Regent Inc.
Luitpold Pharmaceuticals
Pharmacosmos A/S
Sanofi US
Vifor Fresenius Medical Care Renal Pharma
Vifor Pharma Ltd.
Read the full report: https://www.reportlinker.com/p06051284/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Iron Deficiency Anemia (IDA) - An Overview
Recent Market Activity
Intravenous (IV) Iron Drugs Market - A Quick Primer
US and Europe Dominate IV Iron Market
Asia-Pacific - The Fastest Growing Market
Leading Intravenous Iron Drugs Globally
Leading IV Iron Drugs Available in the Market
Leading Intravenous Iron Drugs: In a Nutshell
Ferinject/Injectafer - The Leading Intravenous Iron Drug Globally
Venofer® - Looses Ground to Ferinject
Feraheme Obtains Broader Label Approval
Feraheme® Obtains FDA Filing Acceptance for Treating All Adult
Patients Suffering from IDA
Gluconate (Ferrlecit® and Nulecit)
Dextran
Global Market Leaders
Intravenous (IV) Iron Drugs - Global Key Competitors Percentage
Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
Allergan Plc. (Ireland)
AMAG Pharmaceuticals, Inc. (USA)
Daiichi Sankyo, Inc. (USA)
Luitpold Pharmaceuticals, Inc. (USA)
American Regent, Inc. (USA)
Pharmacosmos A/S (Denmark)
Sanofi US (USA)
Vifor Pharma Ltd. (Switzerland)
Vifor Fresenius Medical Care Renal Pharma (Switzerland)
3. MARKET TRENDS & DRIVERS
Expanding Pool of ESRD and CKD Patients - The Major Growth
Driver for Intravenous (IV) Iron Drugs
ESRD Prevalence Statistics: An Opportunity Indicator
Increase in Healthcare Spending Bodes Well for Intravenous Iron
Drugs Market
Dialysis Patients - A Major Market for Intravenous Iron
Supplements
Ageing Population Drives Demand for IV Iron Drugs
Shifting Preference from Oral Iron Drugs to Intravenous Iron Drugs
Comparison of Ferrous Salts with IV Iron Therapy
Other Chronic Diseases with IDA Offer Prospects for IV Iron Drugs
Anemia in Heart Failure - A Market with Huge Potential
Chemotherapy Induced Anemia to Promote IV Iron Supplements
Correction of IDA in Pregnancy Signals Opportunities
Women?s Health - A Key Growth Opportunity
Perioperative and Postoperative Anemia - A Niche Market Beckons
Adverse Reactions of IV Iron Preparations Raise Concerns
Dosing Limitations Plague IV Iron Market
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2020 through 2027 and % CAGR
Table 2: World Historic Review for Intravenous (IV) Iron Drugs
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 3: World 15-Year Perspective for Intravenous (IV) Iron
Drugs by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa Markets for Years 2012,
2021 & 2027
Table 4: World Recent Past, Current & Future Analysis for Iron
Sucrose by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR
Table 5: World Historic Review for Iron Sucrose by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 6: World 15-Year Perspective for Iron Sucrose by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
Table 7: World Recent Past, Current & Future Analysis for Other
Product Types by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR
Table 8: World Historic Review for Other Product Types by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 9: World 15-Year Perspective for Other Product Types by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
Table 10: World Recent Past, Current & Future Analysis for
Chronic Kidney Disease by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2020 through 2027 and % CAGR
Table 11: World Historic Review for Chronic Kidney Disease by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 12: World 15-Year Perspective for Chronic Kidney Disease
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
Table 13: World Recent Past, Current & Future Analysis for
Inflammatory Bowel Disease by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2020 through 2027 and % CAGR
Table 14: World Historic Review for Inflammatory Bowel Disease
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 15: World 15-Year Perspective for Inflammatory Bowel
Disease by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2021 &
2027
Table 16: World Recent Past, Current & Future Analysis for
Cancer by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR
Table 17: World Historic Review for Cancer by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 18: World 15-Year Perspective for Cancer by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027
Table 19: World Recent Past, Current & Future Analysis for
Other Applications by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR
Table 20: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 21: World 15-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
Table 22: World Recent Past, Current & Future Analysis for
Ferric Carboxymaltose by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2020 through 2027 and % CAGR
Table 23: World Historic Review for Ferric Carboxymaltose by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 24: World 15-Year Perspective for Ferric Carboxymaltose
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
Table 25: World Recent Past, Current & Future Analysis for Iron
Dextran by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR
Table 26: World Historic Review for Iron Dextran by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 27: World 15-Year Perspective for Iron Dextran by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
Table 28: World Intravenous (IV) Iron Drugs Market Analysis of
Annual Sales in US$ Million for Years 2012 through 2027
III. MARKET ANALYSIS
UNITED STATES
Intravenous (IV) Iron Drugs Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in the United States for 2022
(E)
Table 29: USA Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Product Type - Ferric
Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR
Table 30: USA Historic Review for Intravenous (IV) Iron Drugs
by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron
Sucrose and Other Product Types Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 31: USA 15-Year Perspective for Intravenous (IV) Iron
Drugs by Product Type - Percentage Breakdown of Value Sales for
Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other
Product Types for the Years 2012, 2021 & 2027
Table 32: USA Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Application - Chronic Kidney
Disease, Cancer, Inflammatory Bowel Disease and Other
Applications - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 33: USA Historic Review for Intravenous (IV) Iron Drugs
by Application - Chronic Kidney Disease, Cancer, Inflammatory
Bowel Disease and Other Applications Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 34: USA 15-Year Perspective for Intravenous (IV) Iron
Drugs by Application - Percentage Breakdown of Value Sales for
Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and
Other Applications for the Years 2012, 2021 & 2027
CANADA
Table 35: Canada Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Product Type - Ferric
Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR
Table 36: Canada Historic Review for Intravenous (IV) Iron
Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran,
Iron Sucrose and Other Product Types Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 37: Canada 15-Year Perspective for Intravenous (IV) Iron
Drugs by Product Type - Percentage Breakdown of Value Sales for
Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other
Product Types for the Years 2012, 2021 & 2027
Table 38: Canada Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Application - Chronic Kidney
Disease, Cancer, Inflammatory Bowel Disease and Other
Applications - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 39: Canada Historic Review for Intravenous (IV) Iron
Drugs by Application - Chronic Kidney Disease, Cancer,
Inflammatory Bowel Disease and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 40: Canada 15-Year Perspective for Intravenous (IV) Iron
Drugs by Application - Percentage Breakdown of Value Sales for
Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and
Other Applications for the Years 2012, 2021 & 2027
JAPAN
Intravenous (IV) Iron Drugs Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Japan for 2022 (E)
Table 41: Japan Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Product Type - Ferric
Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR
Table 42: Japan Historic Review for Intravenous (IV) Iron Drugs
by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron
Sucrose and Other Product Types Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 43: Japan 15-Year Perspective for Intravenous (IV) Iron
Drugs by Product Type - Percentage Breakdown of Value Sales for
Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other
Product Types for the Years 2012, 2021 & 2027
Table 44: Japan Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Application - Chronic Kidney
Disease, Cancer, Inflammatory Bowel Disease and Other
Applications - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 45: Japan Historic Review for Intravenous (IV) Iron Drugs
by Application - Chronic Kidney Disease, Cancer, Inflammatory
Bowel Disease and Other Applications Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 46: Japan 15-Year Perspective for Intravenous (IV) Iron
Drugs by Application - Percentage Breakdown of Value Sales for
Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and
Other Applications for the Years 2012, 2021 & 2027
CHINA
Intravenous (IV) Iron Drugs Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in China for 2022 (E)
Table 47: China Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Product Type - Ferric
Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR
Table 48: China Historic Review for Intravenous (IV) Iron Drugs
by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron
Sucrose and Other Product Types Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 49: China 15-Year Perspective for Intravenous (IV) Iron
Drugs by Product Type - Percentage Breakdown of Value Sales for
Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other
Product Types for the Years 2012, 2021 & 2027
Table 50: China Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Application - Chronic Kidney
Disease, Cancer, Inflammatory Bowel Disease and Other
Applications - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 51: China Historic Review for Intravenous (IV) Iron Drugs
by Application - Chronic Kidney Disease, Cancer, Inflammatory
Bowel Disease and Other Applications Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 52: China 15-Year Perspective for Intravenous (IV) Iron
Drugs by Application - Percentage Breakdown of Value Sales for
Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and
Other Applications for the Years 2012, 2021 & 2027
EUROPE
Intravenous (IV) Iron Drugs Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Europe for 2022 (E)
Table 53: Europe Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Geographic Region - France,
Germany, Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 54: Europe Historic Review for Intravenous (IV) Iron
Drugs by Geographic Region - France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 55: Europe 15-Year Perspective for Intravenous (IV) Iron
Drugs by Geographic Region - Percentage Breakdown of Value
Sales for France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets for Years 2012, 2021 & 2027
Table 56: Europe Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Product Type - Ferric
Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR
Table 57: Europe Historic Review for Intravenous (IV) Iron
Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran,
Iron Sucrose and Other Product Types Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 58: Europe 15-Year Perspective for Intravenous (IV) Iron
Drugs by Product Type - Percentage Breakdown of Value Sales for
Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other
Product Types for the Years 2012, 2021 & 2027
Table 59: Europe Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Application - Chronic Kidney
Disease, Cancer, Inflammatory Bowel Disease and Other
Applications - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 60: Europe Historic Review for Intravenous (IV) Iron
Drugs by Application - Chronic Kidney Disease, Cancer,
Inflammatory Bowel Disease and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 61: Europe 15-Year Perspective for Intravenous (IV) Iron
Drugs by Application - Percentage Breakdown of Value Sales for
Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and
Other Applications for the Years 2012, 2021 & 2027
FRANCE
Intravenous (IV) Iron Drugs Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in France for 2022 (E)
Table 62: France Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Product Type - Ferric
Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR
Table 63: France Historic Review for Intravenous (IV) Iron
Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran,
Iron Sucrose and Other Product Types Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 64: France 15-Year Perspective for Intravenous (IV) Iron
Drugs by Product Type - Percentage Breakdown of Value Sales for
Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other
Product Types for the Years 2012, 2021 & 2027
Table 65: France Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Application - Chronic Kidney
Disease, Cancer, Inflammatory Bowel Disease and Other
Applications - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 66: France Historic Review for Intravenous (IV) Iron
Drugs by Application - Chronic Kidney Disease, Cancer,
Inflammatory Bowel Disease and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 67: France 15-Year Perspective for Intravenous (IV) Iron
Drugs by Application - Percentage Breakdown of Value Sales for
Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and
Other Applications for the Years 2012, 2021 & 2027
GERMANY
Intravenous (IV) Iron Drugs Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Germany for 2022 (E)
Table 68: Germany Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Product Type - Ferric
Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR
Table 69: Germany Historic Review for Intravenous (IV) Iron
Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran,
Iron Sucrose and Other Product Types Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 70: Germany 15-Year Perspective for Intravenous (IV) Iron
Drugs by Product Type - Percentage Breakdown of Value Sales for
Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other
Product Types for the Years 2012, 2021 & 2027
Table 71: Germany Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Application - Chronic Kidney
Disease, Cancer, Inflammatory Bowel Disease and Other
Applications - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 72: Germany Historic Review for Intravenous (IV) Iron
Drugs by Application - Chronic Kidney Disease, Cancer,
Inflammatory Bowel Disease and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 73: Germany 15-Year Perspective for Intravenous (IV) Iron
Drugs by Application - Percentage Breakdown of Value Sales for
Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and
Other Applications for the Years 2012, 2021 & 2027
ITALY
Table 74: Italy Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Product Type - Ferric
Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR
Table 75: Italy Historic Review for Intravenous (IV) Iron Drugs
by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron
Sucrose and Other Product Types Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 76: Italy 15-Year Perspective for Intravenous (IV) Iron
Drugs by Product Type - Percentage Breakdown of Value Sales for
Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other
Product Types for the Years 2012, 2021 & 2027
Table 77: Italy Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Application - Chronic Kidney
Disease, Cancer, Inflammatory Bowel Disease and Other
Applications - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 78: Italy Historic Review for Intravenous (IV) Iron Drugs
by Application - Chronic Kidney Disease, Cancer, Inflammatory
Bowel Disease and Other Applications Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 79: Italy 15-Year Perspective for Intravenous (IV) Iron
Drugs by Application - Percentage Breakdown of Value Sales for
Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and
Other Applications for the Years 2012, 2021 & 2027
UNITED KINGDOM
Intravenous (IV) Iron Drugs Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in the United Kingdom for 2022
(E)
Table 80: UK Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Product Type - Ferric
Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR
Table 81: UK Historic Review for Intravenous (IV) Iron Drugs by
Product Type - Ferric Carboxymaltose, Iron Dextran, Iron
Sucrose and Other Product Types Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 82: UK 15-Year Perspective for Intravenous (IV) Iron
Drugs by Product Type - Percentage Breakdown of Value Sales for
Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other
Product Types for the Years 2012, 2021 & 2027
Table 83: UK Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Application - Chronic Kidney
Disease, Cancer, Inflammatory Bowel Disease and Other
Applications - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 84: UK Historic Review for Intravenous (IV) Iron Drugs by
Application - Chronic Kidney Disease, Cancer, Inflammatory
Bowel Disease and Other Applications Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 85: UK 15-Year Perspective for Intravenous (IV) Iron
Drugs by Application - Percentage Breakdown of Value Sales for
Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and
Other Applications for the Years 2012, 2021 & 2027
SPAIN
Table 86: Spain Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Product Type - Ferric
Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR
Table 87: Spain Historic Review for Intravenous (IV) Iron Drugs
by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron
Sucrose and Other Product Types Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 88: Spain 15-Year Perspective for Intravenous (IV) Iron
Drugs by Product Type - Percentage Breakdown of Value Sales for
Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other
Product Types for the Years 2012, 2021 & 2027
Table 89: Spain Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Application - Chronic Kidney
Disease, Cancer, Inflammatory Bowel Disease and Other
Applications - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 90: Spain Historic Review for Intravenous (IV) Iron Drugs
by Application - Chronic Kidney Disease, Cancer, Inflammatory
Bowel Disease and Other Applications Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 91: Spain 15-Year Perspective for Intravenous (IV) Iron
Drugs by Application - Percentage Breakdown of Value Sales for
Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and
Other Applications for the Years 2012, 2021 & 2027
RUSSIA
Table 92: Russia Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Product Type - Ferric
Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR
Table 93: Russia Historic Review for Intravenous (IV) Iron
Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran,
Iron Sucrose and Other Product Types Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 94: Russia 15-Year Perspective for Intravenous (IV) Iron
Drugs by Product Type - Percentage Breakdown of Value Sales for
Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other
Product Types for the Years 2012, 2021 & 2027
Table 95: Russia Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Application - Chronic Kidney
Disease, Cancer, Inflammatory Bowel Disease and Other
Applications - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR
Table 96: Russia Historic Review for Intravenous (IV) Iron
Drugs by Application - Chronic Kidney Disease, Cancer,
Inflammatory Bowel Disease and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 97: Russia 15-Year Perspective for Intravenous (IV) Iron
Drugs by Application - Percentage Breakdown of Value Sales for
Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and
Other Applications for the Years 2012, 2021 & 2027
REST OF EUROPE
Table 98: Rest of Europe Recent Past, Current & Future Analysis
for Intravenous (IV) Iron Drugs by Product Type - Ferric
Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR
Table 99: Rest of Europe Historic Review for Intravenous (IV)
Iron Drugs by Product Type - Ferric Carboxymaltose, Iron
Dextran, Iron Sucrose and Other Product Types Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 100: Rest of Europe 15-Year Perspective for Intravenous
(IV) Iron Drugs by Product Type - Percentage Breakdown of Value
Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and
Other Product Types for the Years 2012, 2021 & 2027
Table 101: Rest of Europe Recent Past, Current & Future
Analysis for Intravenous (IV) Iron Drugs by Application -
Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and
Other Applications - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR
Table 102: Rest of Europe Historic Review for Intravenous (IV)
Iron Drugs by Application - Chronic Kidney Disease, Cancer,
Inflammatory Bowel Disease and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 103: Rest of Europe 15-Year Perspective for Intravenous
(IV) Iron Drugs by Application - Percentage Breakdown of Value
Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel
Disease and Other Applications for the Years 2012, 2021 & 2027
ASIA-PACIFIC
Intravenous (IV) Iron Drugs Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
Table 104: Asia-Pacific Recent Past, Current & Future Analysis
for Intravenous (IV) Iron Drugs by Geographic Region -
Australia, India, South Korea and Rest of Asia-Pacific Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 105: Asia-Pacific Historic Review for Intravenous (IV)
Iron Drugs by Geographic Region - Australia, India, South Korea
and Rest of Asia-Pacific Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 106: Asia-Pacific 15-Year Perspective for Intravenous
(IV) Iron Drugs by Geographic Region - Percentage Breakdown of
Value Sales for Australia, India, South Korea and Rest of
Asia-Pacific Markets for Years 2012, 2021 & 2027
Table 107: Asia-Pacific Recent Past, Current & Future Analysis
for Intravenous (IV) Iron Drugs by Product Type - Ferric
Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2020 through 2027 and % CAGR
Table 108: Asia-Pacific Historic Review for Intravenous (IV)
Iron Drugs by Product Type - Ferric Carboxymaltose, Iron
Dextran, Iron Sucrose and Other Product Types Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 109: Asia-Pacific 15-Year Perspective for Intravenous
(IV) Iron Drugs by Product Type - Percentage Breakdown of Value
Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06051284/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
